Table 3.
Base case results of the cost-effectiveness analysis for three COVID-19 vaccines.
Strategy | Effectiveness (QALD) | Incremental QALD | Cost (USD) | Incremental cost | ICUR |
---|---|---|---|---|---|
Vaccination | |||||
Moderna | 179.8286 | 0.8284 | 155.4759 | −266.0500 | −321.1441 |
Pfizer | 179.8120 | 0.8119 | 131.8955 | −289.6303 | −356.7512 |
AstraZeneca | 179.7458 | 0.7456 | 166.9397 | −254.5862 | −341.4381 |
No vaccination | 179.0002 | 421.5258 | – |
ICUR: incremental cost-utility ratio; QALD: quality-adjusted life day.